
Is MANE (Veradermics, Incorporated) Halal or Haram?
Veradermics easily passes all AAOIFI Shariah screens, making it a fully compliant biotechnology investment. The company operates with a pristine balance sheet, carrying 0.0% debt to market cap and holding just 1.6% in cash and interest-bearing securities. Furthermore, it derives zero interest income, ensuring its revenues remain perfectly aligned with Islamic financial standards.
Price Chart (5D)
MANE — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-06-08 | 93.79 | 96.98 | 90.18 | 90.32 | 426K | -3.70% |
| 2026-06-05 | 100.12 | 101.82 | 90.36 | 91.69 | 549K | -8.42% |
| 2026-06-04 | 97.17 | 103.25 | 95.90 | 101.23 | 440K | +4.18% |
| 2026-06-03 | 97.56 | 97.98 | 95.00 | 96.74 | 579K | -0.84% |
| 2026-06-02 | 101.51 | 104.04 | 97.61 | 98.18 | 428K | -3.28% |
| 2026-06-01 | 101.40 | 105.00 | 99.00 | 101.51 | 510K | +0.11% |
| 2026-05-29 | 105.07 | 105.50 | 94.52 | 100.91 | 1.2M | -3.96% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for MANE
Business Activity
Permissible
Veradermics passes the business activity screen because developing therapeutics like VDPHL01 for dermatologic conditions and hair loss is a permissible, life-enhancing medical activity under Islamic principles.
Debt / Market Cap
0.00%
Interest Income
0.00%
Cash & Securities
1.55%
About Veradermics, Incorporated (MANE)
Veradermics, Incorporated is a biopharmaceutical company specializing in novel therapeutics for dermatologic and aesthetic conditions. Its pipeline features targeted treatments like VDPHL01, an oral, non-hormonal therapy for chronic hair loss, alongside microarray patch technologies for common warts and alopecia.
For Muslim investors utilizing HalalStocks.co.uk, Veradermics represents a fully Halal investment opportunity within the healthcare sector. The company successfully passed all four AAOIFI screening criteria, meaning its core medical operations and financial structures align strictly with Islamic principles.
From an Islamic finance perspective, the company boasts an exceptionally clean balance sheet with a 0.0% debt-to-market capitalization ratio. Additionally, its interest income stands at 0.00% and cash reserves sit at a minimal 1.6%, eliminating concerns regarding riba-generating assets or impermissible liquidity.
Since there is no major scholarly debate regarding its core biotechnology operations, investors can hold this stock with confidence. However, shareholders should continue to monitor future clinical trial funding mechanisms to ensure the company does not take on conventional debt as its pipeline scales.
MANE Key Financial Statistics
Revenue
$0
Net Income
$-26.5M
EPS (Diluted)
$-0.14
Stock Price
91.66
Beta
—
52-Week Range
32-101.81
Total Debt
$0
Total Equity
$54.7M
Current Ratio
11.77
MANE Financial Health & Profitability
Profit Margins
Net Cash
$53.1M
Cash: $53.1M — Debt: $0
R&D Spending
$23.3M
% of Revenue
0%
Frequently Asked Questions About MANE
Is MANE (Veradermics, Incorporated) stock halal to invest in?▾
What does Veradermics, Incorporated do?▾
What screening criteria were used for MANE?▾
Does MANE require income purification?▾
When was MANE last screened?▾
Disclaimer
This shariah compliance assessment for MANE (Veradermics, Incorporated) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-27.